SC Filed 2023-11-01 Event — SEC 0000947871-23-001027 →

ORBIMED ADVISORS LLC → Apollomics Inc. APLMW

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 7/100 · Filer 90d Win Rate: 25% · Hist. 90d Edge: -5.4%

Filer track record (12 filings): 25% 90d win rate, +0.0% 90d edge
Moderate short days-to-cover (3.8 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

8 transactions

3 buys · 0 sales · 4 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

145 filings by this filer

144 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 3.82

38,378 shares short · 0.0% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-09-15	LIN PETER KUAN-HOW	officer	Option exercise	10,000	—	—
2026-09-15	LIN PETER KUAN-HOW	officer	F	3,416	$24.02	$82K
2026-09-15	LIN PETER KUAN-HOW	officer	Option exercise	10,000	—	—
2026-09-15	Yen Hung Hsien	director	Option exercise	500	—	—
2026-09-15	Yen Hung Hsien	director	Option exercise	500	—	—
2026-09-14	LIN PETER KUAN-HOW	officer	Award	6,000	$23.18	$139K
2026-09-14	Yen Hung Hsien	director	Award	2,000	$23.18	$46K
2026-08-14	Chen Yi-Kuei	director, officer	Buy	20,000	$15.00	$300K

Other 13D/G Filings on Apollomics Inc.

Filed	Form	Filer	Stake	Shares
2026-08-17	SCHEDULE 13D/A	Chen Hung-Wen	49.76%	1,453,029	view →
2026-08-14	SCHEDULE 13D/A	Chen Yi-Kuei	4.97%	145,171	view →
2026-04-08	SCHEDULE 13D	Chen Yi-Kuei	5.30%	115,071	view →
2026-04-06	SCHEDULE 13D/A	Chen Hung-Wen	41.80%	901,362	view →
2023-10-02	SC	ORBIMED ADVISORS LLC	—	—	view →

Other Filings by ORBIMED ADVISORS LLC

Filed	Form	Issuer	Stake	Shares
2026-10-08	SCHEDULE 13D/A	ArriVent BioPharma, Inc.	5.80%	2,875,962	view →
2026-10-02	SCHEDULE 13D	ADARx Pharmaceuticals, Inc.	14.00%	14,913,764	view →
2026-09-25	SCHEDULE 13D	Electra Therapeutics, Inc.	11.00%	6,885,170	view →
2026-09-10	SCHEDULE 13D/A	Braveheart Bio, Inc.	13.50%	12,175,159	view →
2026-08-18	SCHEDULE 13D	BlossomHill Therapeutics, Inc.	8.90%	2,714,279	view →
2026-08-18	SCHEDULE 13D	Braveheart Bio, Inc.	17.20%	12,175,159	view →
2026-08-10	SCHEDULE 13D/A	MBX Biosciences, Inc.	—	3,074,853	view →
2026-08-05	SCHEDULE 13D	Yarrow Bioscience, Inc.	9.97%	266,306	view →
2026-07-29	SCHEDULE 13D	Scribe Therapeutics, Inc.	7.20%	1,348,825	view →
2026-07-20	SCHEDULE 13D/A	Q32 Bio Inc.	—	4,127,987	view →
2026-06-24	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	—	6,774,507	view →
2026-06-17	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	10.93%	7,634,630	view →
2026-06-15	SCHEDULE 13D/A	Shattuck Labs, Inc. STTK	—	9,021,127	view →
2026-06-01	SCHEDULE 13D/A	Q32 Bio Inc. QTTB	—	4,127,987	view →
2026-04-10	SCHEDULE 13D/A	Adicet Bio, Inc. ACET	8.80%	844,787	view →
2026-01-27	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	10.30%	8,609,091	view →
2025-10-10	SCHEDULE	Adicet Bio, Inc. ACET	9.60%	14,772,598	view →
2025-09-30	SCHEDULE	MBX Biosciences, Inc. MBX	9.00%	4,002,887	view →
2025-07-21	SCHEDULE	Passage BIO, Inc. PASG	7.82%	243,878	view →
2025-05-14	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	12.20%	9,785,423	view →

Showing 20 of 144

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →